A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 2, 2011, Pages 191-195

  Li, Guoqiang ^a   Luo, Xiaodi ^a   He, Jiaying ^a   Zhu, Zeyao ^a   Yu, Gang ^a   Qin, Huijuan ^a   Zeng, Tao ^a   Liu, Zhiming ^a   Wu, Shiyang ^a   Xu, Jiasen ^a   Ren Heidenreich, Lifen ^a  

^a Guangzhou Technology Innovation Base   (China)

Author keywords

allele specific primer extension; EGFR signaling pathway; liquidchip; somatic mutations

Indexed keywords

B RAF KINASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; K RAS PROTEIN; PARAFFIN; PIK3CA PROTEIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CANCER TISSUE; DIAGNOSTIC ACCURACY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; HYBRIDIZATION; LIQUIDCHIP PLATFORM; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOMATIC MUTATION; TISSUE SECTION; VALIDATION PROCESS;

ALLELES; DNA MUTATIONAL ANALYSIS; FORMALDEHYDE; HUMANS; MUTATION; NEOPLASMS; PARAFFIN EMBEDDING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TISSUE FIXATION;

EID: 79952085858     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.040     Document Type: Article

References (15)

1. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70. (Pubitemid 32963812)
2. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004;10:4227-32.
3. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25.
4. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
5. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44. (Pubitemid 41058345)
6. Zhang X, Chang A. Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 2008;5:209-17.
7. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7. (Pubitemid 39100331)
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
9. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77.
10. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.
11. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
12. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008;68:9221-30.
13. Tsuchihashi Z, Dracopoli NC. Progress in high throughput SNP genotyping methods. Pharmacogenomics J 2002;2:103-10. (Pubitemid 34982213)
14. Wu S, Zhu Z, He J, Luo X, Xu J, Ren-Heidenreich L. A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples. Clin Chem Lab Med 2010;48:1103-6.
15. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007;13:4954-5. (Pubitemid 47502057)